Cost-effectiveness of screening and treating anal pre-cancerous lesions among gay, bisexual and other men who have sex with men living with HIV

被引:5
作者
Cheng, Qinglu [1 ]
Poynten, Mary [1 ]
Jin, Fengyi [1 ]
Grulich, Andrew [1 ]
Ong, Jason J. [2 ,3 ,4 ]
Hillman, Richard J. [1 ,5 ]
Hruby, George [6 ,7 ,8 ]
Howard, Kirsten [7 ]
Newall, Anthony [9 ]
Boettiger, David C. [1 ,10 ,11 ]
机构
[1] Univ New South Wales, Kirby Inst, Wallace Wurth Bldg, Sydney 2052, Australia
[2] Monash Univ, Cent Clin Sch, Melbourne, Australia
[3] London Sch Hyg & Trop Med, London, England
[4] Alfred Hlth, Melbourne Sexual Hlth Ctr, Melbourne, Australia
[5] St Vincents Hosp, Dysplasia & Anal Canc Serv, Sydney, Australia
[6] Royal North Shore Hosp, Northern Sydney Canc Ctr, Sydney, Australia
[7] Univ Sydney, Sydney, Australia
[8] Genesis Canc Care, Sydney, Australia
[9] Univ New South Wales, Sch Populat Hlth, Sydney, Australia
[10] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA
[11] Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Bangkok, Thailand
来源
LANCET REGIONAL HEALTH-WESTERN PACIFIC | 2023年 / 32卷
基金
美国国家卫生研究院; 英国医学研究理事会;
关键词
Anal; Cancer; High-grade squamous intra-epithelial; HIV; Men; SQUAMOUS INTRAEPITHELIAL LESIONS; PREFERENCE-BASED MEASURE; VIRUS-POSITIVE MEN; HUMAN-PAPILLOMAVIRUS; CLINICAL EFFECTIVENESS; CANCER; NEOPLASIA; HEALTH; PREVALENCE; INFECTION;
D O I
10.1016/j.lanwpc.2022.100676
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Gay, bisexual and other men who have sex with men (GBM) living with HIV have a substantially elevated risk of anal cancer (85 cases per 100,000 person-years vs 1-2 cases per 100,000 person-years in the general population). The precursor to anal cancer is high-grade squamous intraepithelial lesion (HSIL). Findings regarding the cost-effectiveness of HSIL screening and treatment in GBM are conflicting. Using recent data on HSIL natural history and treatment effectiveness, we aimed to improve upon earlier models. Methods We developed a Markov cohort model populated using observational study data and published literature. Our study population was GBM living with HIV aged >= 35 years. We used a lifetime horizon and framed our model on the Australian healthcare perspective. The intervention was anal HSIL screening and treatment. Our primary outcome was the incremental cost-effectiveness ratio (ICER) as cost per quality-adjusted life-year (QALY) gained. Findings Anal cancer incidence was estimated to decline by 44-70% following implementation of annual HSIL screening and treatment. However, for the most cost-effective screening method assessed, the ICER relative to current practice, Australian Dollar (AUD) 135,800 per QALY gained, remained higher than Australia's commonly accepted willingness-to-pay threshold of AUD 50,000 per QALY gained. In probabilistic sensitivity analyses, HSIL screening and treatment had a 20% probability of being cost-effective. When the sensitivity and specificity of HSIL screening were enhanced beyond the limits of current technology, without an increase in the cost of screening, ICERs improved but were still not cost-effective. Cost-effectiveness was achieved with a screening test that had 95% sensitivity, 95% specificity, and cost <= AUD 24 per test. Interpretation Establishing highly sensitive and highly specific HSIL screening methods that cost less than currently available techniques remains a research priority.
引用
收藏
页数:10
相关论文
共 40 条
[1]  
Australian Government, PHARM BEN SCHEM
[2]  
Australian Government, 2020, MEDICARE BENEFITS SC
[3]  
Australian HIV Observational Database, 2002, HIV Med, V3, P28
[4]   The estimation of a preference-based measure of health from the SF-36 [J].
Brazier, J ;
Roberts, J ;
Deverill, M .
JOURNAL OF HEALTH ECONOMICS, 2002, 21 (02) :271-292
[5]   The estimation of a preference-based measure of health from the SF-12 [J].
Brazier, JE ;
Roberts, J .
MEDICAL CARE, 2004, 42 (09) :851-859
[6]   Evaluating the efficacy of treatment options for anal intraepithelial neoplasia: a systematic review [J].
Brogden, Danielle R. L. ;
Walsh, Una ;
Pellino, Gianluca ;
Kontovounisios, Christos ;
Tekkis, Paris ;
Mills, Sarah C. .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2021, 36 (02) :213-226
[7]  
Cancer Council Australia, AUSTR SUCC STOR HPV
[8]   A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale [J].
Clifford, Gary M. ;
Georges, Damien ;
Shiels, Meredith S. ;
Engels, Eric A. ;
Albuquerque, Andreia ;
Poynten, Isobel Mary ;
de Pokomandy, Alexandra ;
Easson, Alexandra M. ;
Stier, Elizabeth A. .
INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (01) :38-47
[9]   Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer [J].
Czoski-Murray, C. ;
Karnon, J. ;
Jones, R. ;
Smith, K. ;
Kinghorn, G. .
HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 (53) :1-+
[10]   Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis [J].
De Vuyst, Hugo ;
Clifford, Gary M. ;
Nascimento, Maria Claudia ;
Madeleine, Margaret M. ;
Franceschi, Silvia .
INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (07) :1626-1636